Copernicus Therapeutics
Copernicus Therapeutics is a Cleveland clinical-stage biotechnology company advancing non-viral gene therapies on its STELLAR delivery platform.
Founded
1995Copernicus Therapeutics is a Cleveland clinical-stage biotechnology company advancing non-viral gene therapies on its STELLAR delivery platform.
STELLAR's compacted DNA nanoparticles differ from AAV vectors on the points that matter for chronic genetic disease: they provoke no viral-capsid immune response, so doses can be repeated; they carry payloads larger than viral capsids accommodate; and they avoid the complex biologics manufacturing that AAV production requires, using simpler cGMP processes with off-the-shelf components. Human Phase 1/2 cystic fibrosis data showed CFTR correction across dose levels, giving the platform clinical evidence most preclinical delivery technologies lack.
The company holds FDA Orphan Drug designations for both cystic fibrosis and Stargardt disease. Its cystic fibrosis program restores CFTR function regardless of the underlying mutation, positioning it against modulators that address only specific mutation classes and leaving the majority of patients without a matched therapy as its addressable population.
Source: copernicustherapeutics.com
Copernicus frames its cystic fibrosis opportunity around more than 85,000 patients worldwide, a figure it pairs with company communications on LinkedIn noting that roughly 20% of eligible patients are not taking a CFTR modulator. Its Phase 2b study is designed and powered to support potential registration, making cystic fibrosis the platform's nearest regulatory milestone.
Beyond cystic fibrosis, the pipeline extends into Stargardt disease, additional rare genetic disorders, Parkinson disease, diabetic retinopathy, and opioid use disorder. The company's pipeline page states an openness to partnering arrangements across these programs.
Source: copernicustherapeutics.com
STELLAR is Copernicus Therapeutics' non-viral gene delivery platform built on compacted DNA nanoparticles that traffic therapeutic payloads through receptor-mediated pathways directly to the cell nucleus. Because the cargo is condensed DNA rather than a viral vector, payload size is effectively unconstrained, and the system is designed to permit repeat dosing without activating toll-like receptor pathways that limit viral approaches.
The platform relies on cGMP-compatible off-the-shelf components with shelf life exceeding three years at refrigerator temperature, and its delivery has been validated across lung, eye, and brain tissue. STELLAR powers Copernicus programs in cystic fibrosis, which is Phase 2b-ready; in Stargardt disease, which is IND-enabling; and in preclinical rare genetic disorders.
Source: copernicustherapeutics.com